1. MacDorman MF, Mathews TJ. Recent trends in infant mortality in the US. National Center for Health Statistics. Centers for Disease Control and Prevention. US Department of Health and Human Services. NCHS Data Brief Number 9, October 2008. http://www.cdc.gov/nchs/data/databriefs/db09.htm.
2. Avery GB, Randolph JG, Weaver T. Gastric acidity in the first day of life. Pediatrics 1966;37:1005–1007.
3. Agunod M, Yamaguchi N, Lopex R, et al. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969;14:400–414.
4. Huang NN, High RN. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953;42:657–668.
5. Silverio J, Poole JW. Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics 1973;51:578–580.
6. O'Connor WJ, Warren GH, Edrada LS, et al. Serum concentrations of sodium nafcillin
in infants during the perinatal period. Antimicrob Agents Chemother 1965;5:220–222.
8. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Drug therapy: Developmental pharmacology—Drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157–1167.
9. Signer E, Fridrich R. Gastric emptying in newborns and young infants. Acta Paediatr Scand 1975;64:525–530.
10. Boreus IO. Plasma concentrations of phenobarbital
in mother and child after combined prenatal and postnatal administration for prophylaxis of hyperbilirubinemia. J Pediatr 1978;93:695.
11. Morselli PL. Serum levels and pharmacokinetics of anticonvulsants in the management of seizure disorders. In: Merkin B, ed. Clinical Pharmacology. Chicago: Mosby Year Book, 1978:89.
12. Tyrala FF, Hillman LS, Hillman RE, et al. Clinical pharmacology of hexa-chlorophene in newborn infants. J Pediatr 1977;91:481–486.
13. McFadden S, Haddow JE. Coma produced by topical application of isopropanol. Pediatrics 1969;43:622–623.
14. Evans NJ, Rutter N, Hadgraft J, et al. Percutaneous administration of theophylline
in preterm infant. J Pediatr 1985;107:307–311.
15. Friis-Hansen B. Body water compartments in children: Changes during growth and related changes in body composition. Pediatrics 1961;28:169–181.
16. Haughey DB, Hilligoss DM, Grassi A, et al. Two-compartment gentamicin
pharmacokinetics in premature neonates: A comparison to adults with decreased glomerular filtration rates. J Pediatr 1980;96: 325–330.
17. Nahata MC, Powell DA, Durrell DE, et al. Effect of gestational age and birth weight on tobramycin
kinetics in newborn infants. J Antimicrob Chemother 1984;14:59–65.
18. Roberts RJ. Pharmacologic principles in therapeutics in infants. In: Drug Therapy in Infants: Pharmacologic Principles and Clinical Experience. Philadelphia, PA: WB Saunders, 1984:3–12.
20. Painter MJ, Pippenger C, MacDonald H, et al. Phenobarbital
and diphenylhydantoin levels in neonates with seizures. J Pediatr 1978;92:315–319.
21. Silverman WA, Anderson DH, Blanc WA, et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956;18:614–624.
22. Odell GB. The dissociation of bilirubin from albumin and its clinical implications. J Pediatr 1959;55:268–279.
23. Morselli PL. Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1976;1:81–98.
24. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108: 776–789.
25. Rane A. Drug metabolism and disposition in infants and children. In: Yaffe JF, ed. Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:32–43.
26. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant: A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 1960;262:787–794.
27. Nahata MC, Powell DA. Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients. Dev Pharmacol Ther 1983;6:23–32.
28. Kuhn R, Nahata MC, Powell DA, et al. Netilmicin pharmacokinetics in newborn infants. Eur J Clin Pharmacol 1986;29:635–637.
29. Cha PCW, Duffy BJ, Walker JS. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther 1992;51:334–342.
30. Edwards DJ, Zarowitz BJ, Slaughter RL. Theophylline
. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:1–47.
31. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin
enantiomers in Japanese children. Clin Pharmacol Ther 2000;68:541–555.
32. Lambert GH, Schoeller DA, Kotake AN, et al. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther 1986;9:375–388.
33. McLeod HL, Krynetski ER, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14: 567–572.
35. Kearin M, Kelly JG, O'Malley K. Digoxin “receptors” in neonates: An explanation of less sensitivity to digoxin than in adults. Clin Pharmacol Ther 1980;28:346–349.
36. Kawai M, Momoi T, Yorifuji, T, et al. Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J Pediatr 1997;130:205–209.
37. Glasgow AM, Boeckx RL, Miller MK, et al. Hyperosmolality in small infants due to propylene glycol. Pediatrics 1983;72:353–355.
38. Hiller JL, Benda GI, Rahatzad M, et al. Benzyl alcohol
toxicity: Impact of mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics 1986;77:500–506.
39. Grossman ER, Walchek A, Freedman H. Tetracyclines and permanent teeth: The relation between dose and tooth color. Pediatrics 1971;47:567–570.
40. American Academy of Pediatrics Committee on Infectious Diseases. The use of systemic fluoroquinolones, policy statement. Pediatrics 2006;118:1287–1292.
41. Kauffman RE, Habersange R. Modification of dosage regimens in disease states of childhood. In: Mirking BL, ed. Clinical Pharmacology and Therapeutics: A Pediatric Perspective. Chicago: Mosby Year Book, 1978:73–88.
42. Roberts RJ. Special considerations in drug therapy in infants. In: Drug Therapy in Infants: Pharmacologic Principles and Clinical Experience. Philadelphia, PA: WB Saunders, 1984:25–35.
44. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: Evaluation, classification, and stratification. Pediatrics 2003;111: 1416–1421.
45. Schwartz Gj, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987;34:571–590.
46. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol 2007;22:1839–1848.
47. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629–637.
48. Lemley KV. Estimating GFR in children: Schwartz redux. Nature Rev Nephrol 2009;5:310–311.
49. Wallace CS, Hall M, Kuhn RJ. Pharmacologic management of cystic fibrosis. Clin Pharm 1993;12:657–674.
50. Daniels SR, Jacobson MS, McCrindle BW, et al. American Heart Association childhood obesity research summit report. Circulation 2009;119:e489–e517.
51. Speiser PW, Rudolf MCJ, Anhalt H, et al. Consensus statement: childhood obesity. J Clin Endocrinol Metab 2005;90(3):1871–1887.
52. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007;25:2063–2069.
53. Behan JW, Yun JP, Proektor MP, et al. Adipocytes impair leukemia treatment in mice. Cancer Res 2009;69:7867.
54. Myers MG, Roberts JF, Mirhig NJ. Effect of gestational age, birth weight, and hypoxemia on the pharmacokinetics of amikacin
in serum of infants. Antimicrob Agents Chemother 1977;11:1027.
55. Bahal-O'Mara N, Jones R, Nahata MC, et al. Pharmacokinetics of phenytoin
in children with acute neurotrauma. Crit Care Med 1995;23:1418–1424.
56. Rana SR. Pain: A subject ignored [letter]. Pediatrics 1987;79:309.
57. Franch LS, Greenberg CS, Stevens B. Pain assessment in infants and children. Pediatr Clin North Am 2000;47:487–512.
58. American Academy of Pediatrics Committee on Fetus and Newborn, American Academy of Pediatrics Section on Surgery, Canadian Paediatric Society Fetus and Newborn Committee, Batton DG, Barrington KJ, Wallman C. Prevention and management of pain in the neonate: an update. Pediatrics 2006;118:2231–2241.
59. Fitzgerald M, Howard RF. The neurobiologic basis of pediatric pain. In: Schechter NL, Berde CB, Yaster M, eds. Pain in Infants, Children, and Adolescents. Baltimore, MD: Lippincott Williams & Wilkins, 2003:19–42.
60. Taddio A, Katz J, Ilersich Al, et al. Effect of neonatal circumcision on pain response during subsequent routine vaccination. Lancet 1997;349:559–603.
61. Taddio A, Ohlsson A, Einarson T, et al. A systematic review of lidocaine-prilocaine cream for neonatal circumcision pain. N Engl J Med 1997;336:1197–1201.
63. Zempsky, WT, Anand KS, Sullivan KM, et al. Lidocaine
iontophoresis for topical anesthesia before intravenous line placement in children. J Pediatr 1998;132:1061–1063.
64. Reis EC
, Holobukov R. Vapocoolant spray is equally effective as EMLA cream in reducing immunization pain in school aged children. Pediatrics 1997;100:5.
65. Bartfield JM, Connis P, Barbera J, et al. Buffered versus plain lidocaine
as a local anesthetic for simple laceration repair. Ann Emerg Med 1990;19:1387–1390.
66. Schechter NL, Berde CB, Yaster M, et al. The pain (and stress) in infants in a neonatal intensive care unit. In: Wong CM, McIntosh N, Menon G, Franck LS, eds. Pain in Infants, Children, and Adolescents. Baltimore, MD: Lippincott Williams & Wilkins, 2003; :669-692.
67. Keen MF. Comparison of intramuscular injection techniques to reduce site discomfort and lesions. Nurs Res 1986;35:207–210.
68. Golianu B, Krane EJ, Galloway KS, et al. Pediatric acute pain management. Pediatr Clin North Am 2000;47:559–587.
69. Chay PCW, Duffy BJ, Walker JS. Pharmacokinetic-pharmacodynamic relationship of morphine in neonates. Clin Pharmacol Ther 1992;51:334–342.
70. Berde CB, Lehn BM, Yee JD, et al. Patient-controlled analgesia in children and adolescents: A randomized, prospective comparison with intramuscular administration of morphine for postoperative analgesia. J Pediatr 1991;118:460–466.
71. Nichols DG, Yaster M, Lynn AM, et al. Disposition and respiratory effects of intrathecal morphine in children. Anesthesiology 1993;79:733–738.
72. Berman W. Whitman V, Marks KH, et al. Inadvertent overadministration of digoxin to low birth weight infants. J Pediatr 1978;92:1024.
73. Zenk KE, Anderson S. Improving the accuracy of minivolume injections. Infusion 1982;Jan-Feb:7–11.
74. Nahata MC, Pai V, Hipple TF. Pediatric Drug Formulations, 5th ed. Cincinnati, OH: Harvey Whitney Books, 2003:1–307.
75. Martin AJ, Campbell DA, Gluyas PA, et al. Characteristics of near-fatal asthma in childhood. Pediatr Pulmonol 1995;20:1–8.
76. Erglin A, Frattarelli DAC. Compliance with pediatric medication regimens. In: Yaffe SJ, ed. Pediatric Pharmacology: Therapeutic Principles in Practice, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:60–68.
77. Matsui D, Barron A, Rieder MJ. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacother 1996;30:586–588.
78. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents, 2007–2008. JAMA. 2010;303:242–249.
79. Cheymol G. Effects of obesity on pharmacokinetics: Implications for drug therapy. Clin Pharmacokinet 2000;39:215–231.
80. Miller JL. Evaluation of inpatient admissions and potential antimicrobial and analgesic dosing errors in overweight children. Ann Pharmacother 2010;44:35–42.
81. Lanski SL, Greenwald M, Perkins A, et al. Herbal therapy use in a pediatric emergency department population: Expect the unexpected. Pediatrics 2003;111:981–985.
82. Institute of Medicine, Committee on Quality of Health Care in American. To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, 2000.
83. Raju TN, Kecskes S, Thornton JP, et al. Medication errors in neonatal and paediatric intensive-care units. Lancet 1989;2:374–376.
84. Folli HL, Poole RL, Benitz WE, et al. Medication error prevention by clinical pharmacists in two children's hospitals. Pediatrics 1987;79:718–722.
85. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114–2120.
86. USP Center for the Advancement of Patient Safety. USP issues recommendations for preventing medication errors in children. January 21, 2003.
87. American Academy of Pediatrics Committee on Drugs and Committee on Hospital Care. Prevention of medication errors in pediatric inpatient setting. Pediatrics 2003;112:431–436.
88. Agency for Healthcare Research and Quality. Making Health Care Safer: A Critical Analysis of Patient Safety Practices. AHRQ Publication No. 01-E058. Washington, DC: Agency for Healthcare Research and Quality, 2001.
89. Larsen GY, Parker HB, Cash J, et al. Standard drug concentrations and smart-pump technology reduce continuous-medication-infusion errors in pediatric patients. Pediatrics 2005;116:21–25.
90. Sauberan JB, Dean LM, Fiedelak J, et al. Origins of and solutions for neonatal medication-dispensing errors. Am J Health System Pharm 2010;67:49–57.
91. Arimura J, Poole RL, Jeng M, et al. Neonatal heparin overdose: a multidisciplinary team approach to medication error prevention. J Pediatr Pharmacol Ther 2008;13:96–98.
92. Joint Commission Sentinel Event Alert. Preventing errors relating to commonly used anticoagulants. 2008; 41.